An overview of Ankylosing Spondylitis and Axial Spondyloarthritis, their diagnosis, symptoms, causes, and treatment options.
Key Takeaways
- AS and AxSpA are closely related conditions differentiated mainly by imaging findings.
- Early diagnosis and intervention are crucial to managing disease progression effectively.
- Genetics, especially HLA-B27, play a major role but the exact cause remains under research.
- Symptoms are diverse and include inflammatory back pain and systemic features like psoriasis and uveitis.
- Osteoporosis can coexist with AS despite new bone formation, complicating management.
Summary
- Ankylosing Spondylitis (AS) and Axial Spondyloarthritis (AxSpA) are part of a group of conditions called spondyloarthritis, affecting the spine and trunk.
- AS is a subgroup of AxSpA known as radiographic AxSpA, characterized by visible changes in imaging such as MRI or X-rays, including spinal fusion.
- Non-radiographic AxSpA shows no visible changes on scans but shares similar symptoms and can progress to radiographic AxSpA.
- Key affected joints include the sacroiliac joints between the sacrum and pelvic bones, where inflammation and structural changes begin.
- Diagnosis involves criteria such as age under 45, chronic back pain over three months, imaging evidence, genetic markers like HLA-B27, and other spondyloarthritis features.
- Symptoms include inflammatory back pain, peripheral arthritis, enthesitis, dactylitis, good response to NSAIDs, family history, psoriasis, inflammatory bowel disease, and uveitis.
- The HLA-B27 gene plays a significant role in susceptibility, though the exact mechanism is unclear; autoimmune theories like the arthritogenic peptide theory are proposed.
- AS patients may paradoxically experience both new bone formation and osteoporosis, possibly due to disrupted bone turnover or reduced physical activity.
- Diagnosis is complex and often missed early; it relies on history, blood tests, imaging, and tools like the SpADE tool to fast-track referrals to rheumatologists.
- Treatment typically begins conservatively, focusing on symptom management and early intervention to prevent progression.











